Abstract: The disclosure provides a PKC inhibitor and a cytotoxic agent for use in therapy, wherein the PKC inhibitor reaches a peak concentration in a subject prior to the cytotoxic agent reaching a peak concentration. The PKC inhibitor and the cytotoxic 5 agent may be used to treat cancer or an autoimmune disease.

Abstract: The present disclosure relates to pharmaceutical formulations comprising imatinib or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease using the formulations.

Abstract: Tricyclic dibenzothiazepine compounds for use in the treatment of CDKL5 disorder. Specifically, a compound of Formula I, or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity for use in the treatment of CDKL5 disorder in a mammal, wherein a compound of Formula I comprises: or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity, wherein: R1 and R3 each independently represent, at each occurrence when used herein, H or C1 to C5 alkyl; R2 represents halo; R4 and R5 each independently represent H; R6 represents —C(O)OR9; X represents CH2, O or S; R9 represents H or C1 to C5 alkyl; and, m is an integer from 1 to 6 inclusive.

Abstract: Tricyclic dibenzothiazepine compounds for use in the treatment of CDKL5 disorder. Specifically, a compound of Formula I, or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity for use in the treatment of CDKL5 disorder in a mammal, wherein a compound of Formula I comprises: or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity, wherein: R1 and R3 each independently represent, at each occurrence when used herein, H or C1 to C5 alkyl; R2 represents halo; R4 and R5 each independently represent H; R6 represents —C(O)OR9; X represents CH2, O or S; R9 represents H or C1 to C5 alkyl; and, m is an integer from 1 to 6 inclusive.

Abstract: Tricyclic dibenzothiazepine compounds for use in the treatment of CDKL5 disorder. Specifically, a compound of Formula I, or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity for use in the treatment of CDKL5 disorder in a mammal, wherein a compound of Formula I comprises: or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity, wherein: R1 and R3 each independently represent, at each occurrence when used herein, H or C1 to C5 alkyl; R2 represents halo; R4 and R5 each independently represent H; R6 represents —C(O)OR9; X represents CH2, O or S; R9 represents H or C1 to C5 alkyl; and, m is an integer from 1 to 6 inclusive.

Abstract: Tricyclic dibenzothiazepine compounds for use in the treatment of respiratory depression.

Abstract: A compound of formula I: or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity, wherein: R1, R2, R3, R4, R5, R6, X and m are as defined herein.

Abstract: Tricyclic dibenzothiazepine compounds for use in the treatment of respiratory depression.

Abstract: A compound of formula I: or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity, wherein: R1, R2, R3, R4, R5, R6, X and m are as defined herein.

Abstract: The present invention provides a means for prevention and treatment of cachexia and other chronic illnesses including but not limited to the promotion of weight gain, reduction or prevention of weight loss by administration of a substance that both reduces the sensitivity of beta-adrenergic receptors and of 5-HT1a receptors. (S)-pindolol, (S)-propranolol, tertatolol or bopindolol are preferred for this purpose.

Abstract: The present invention provides a means for prevention and treatment of cachexia and other chronic illnesses including but not limited to the promotion of weight gain, reduction or prevention of weight loss by administration of a substance that both reduces the sensitivity of beta-adrenergic receptors and of 5-HT1a receptors. (S)-pindolol, (S)-propranolol, tertatolol or bopindolol are preferred for this purpose.

Abstract: 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof is useful for the treatment of pain.

Abstract: Use of 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine or a salt thereof for the manufacture of a medicament for the treatment of functional bowel disorder.

Abstract: 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)-Thieno(2,3-D)pyrimidine or a salt thereof is useful for the treatment of urinary incontinence.

Abstract: (4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine or a salt thereof has value in the treatment of fibromyalgia, obesity, weight gain and other conditions.

Abstract: A liquid or semi-solid topical formulation of buspirone, when applied to human epidermis in vitro (following methods defined herein), results in a transepidermal flux rate of buspirone (individual or mean data) in one or more of the following ranges: 0.1 to 1.1 ?g/cm2/hour as assessed over 5 hours following application; 0.09 to 0.60 ?g/cm2/hour as assessed over 13 hours following application; 0.09 to 0.48 ?g/cm2/hour as assessed over 24 hours following application; 0.08 to 0.46 ?g/cm2/hour as assessed over 30 hours following application; and 0.08 to 0.39 ?g/cm2/hour as assessed over 48 hours following application. Buspirone is useful for the manufacture of a topical medicament for use in the treatment of pruritus or an immune-related skin disease.

Abstract: An activator of PPAR gamma is useful for the treatment of pulmonary fibrosis.

Abstract: Use of 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine or a salt thereof for the manufacture of a medicament for the treatment of functional bowel disorder.

Abstract: 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)-Thieno(2,3-D)pyrimidine or a salt thereof is useful for the treatment of urinary incontinence.

Abstract: An arylazo-substituted imidazole having adrenergic alpha stimulatory activity, is useful for the treatment of stress urinary incontinence.